What is Pfizer's zithromax — revenues:?

Pfizer (PFE) reported zithromax — revenues: of $112M in Q1 2026.

How has Pfizer's zithromax — revenues: changed year-over-year?

Pfizer's zithromax — revenues: decreased by 29.1% year-over-year, from $158M to $112M.

What is the long-term trend for Pfizer's zithromax — revenues:?

Over 4 years (2021 to 2025), Pfizer's zithromax — revenues: has grown at a 9.5% compound annual growth rate (CAGR), from $278M to $400M.

What does zithromax — revenues: mean?

This metric represents the total gross sales generated from the Zithromax product line, which is a key antibiotic therapy within the company's anti-infective portfolio. It reflects the market demand and commercial performance of this specific pharmaceutical asset across global markets. Tracking this revenue stream helps assess the lifecycle maturity and competitive positioning of established legacy products within the broader drug portfolio.

Pfizer PFE Zithromax — Revenues:

Other product segments

Eliquis

$2.17B+12.6%

Prevnar Family

$1.69B+1.8%

Vyndaqel family

$1.6B+7.8%

Ibrance

$1.01B+3.2%

All Other Hospital and Biosimilars

$953M—

All other Primary Care

$654M+7.4%

Padcev

$591M+38.7%

All other Specialty Care

$579M+19.1%

Xtandi

$444M-3.1%

Oncology Biosimilars

$409M+54.9%

Royalty

$396M+28.6%

All other Oncology

$376M-0.3%

Nurtec ODT/Vydura

$353M+42.3%

Lorbrena

$305M+37.4%

Pfizer CentreOne

$289M+5.9%

Comirnaty

$232M-58.9%

Paxlovid

$219M-69.9%

Inlyta

$214M-2.3%

Sulperazon (Outside the U.S. and Canada)

$199M+21.3%

Adcetris

$190M-12.8%

Inflectra

$182M—

Abrysvo

$180M+37.4%

Xeljanz

$180M+40.6%

Braftovi/Mektovi

$174M+27.9%

Zavicefta (Outside the U.S. and Canada)

$150M+11.1%

Enbrel (Outside the U.S. and Canada)

$138M-1.4%

Bosulif

$129M-14.6%

Octagam

$122M—

Tukysa

$122M+19.6%

Orgovyx

$109M—

Genotropin

$93M—

FSME-IMMUN/TicoVac

$81M—

Elrexfio

$80M+33.3%

Cibinqo

$76M+31.0%

Talzenna

$50M+25.0%

Tivdak

$33M0.0%

Similar metrics at other companies

OGNZetia — Revenue

$87M+2.4%

SSRMZinc — Revenue

$1.14M+213%

JAZZZiihera — Revenue from Contract with Customer, Excluding Assessed Tax

$13.3M+565%

ARDXXPHOZAH — Total revenues

$23.3M-0.5%

INCYZYNYZ — Total revenues

$41.39M+1,276%

BMYZeposia — Total Revenues

$118M+10.3%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$138.21B-3.7%

Enterprise value$200.88B-1.3%

P/E11.4×—

P/S2.2×-0.1×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's zithromax — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's zithromax — revenues:?: Pfizer (PFE) reported zithromax — revenues: of $112M in Q1 2026.
How has Pfizer's zithromax — revenues: changed year-over-year?: Pfizer's zithromax — revenues: decreased by 29.1% year-over-year, from $158M to $112M.
What is the long-term trend for Pfizer's zithromax — revenues:?: Over 4 years (2021 to 2025), Pfizer's zithromax — revenues: has grown at a 9.5% compound annual growth rate (CAGR), from $278M to $400M.
What does zithromax — revenues: mean?: This metric represents the total gross sales generated from the Zithromax product line, which is a key antibiotic therapy within the company's anti-infective portfolio. It reflects the market demand and commercial performance of this specific pharmaceutical asset across global markets. Tracking this revenue stream helps assess the lifecycle maturity and competitive positioning of established legacy products within the broader drug portfolio.